Collegium Reports Third Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Collegium (COLL) Xtampza ER Sales More than Double Expectations - William Blair
November 9, 2017 9:50 AM ESTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Collegium Pharmaceutical (NASDAQ: COLL) following Q3 results which showed Xtampza ER sales for the third quarter came in at $11.95 million, well above our expectation of $4.8 million and consensus of $5.3 million. Lugo notes that... More
